Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 9Lymphoma, Large-Cell, Anaplastic 4Carcinoma 4Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Brain Neoplasms 2Adenocarcinoma 2ALK-positive Advanced NSCLC 2Sexual Dysfunction, Physiological 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Meningioma 1Granuloma, Plasma Cell 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Ependymoma 1Disease Progression 1Carcinoma, Pancreatic Ductal 1Breast Neoplasms 1ALK-positive NSCLC 1ALK+ Advanced NSCLC 1

Interventions

Crizotinib 2lorlatinib 1ceritinib 1brigatinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ALK-positive NSCLC × brigatinib × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡